^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Cereblon modulator

    Related drugs:
    2d
    Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. (PubMed, Blood)
    Finally, we demonstrate the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy in vivo. Overall, our data show that Mezigdomide treatment improves anti-myeloma T cell therapy efficacy and reduces T cell dysfunction by abrogating Ikaros-mediated upregulation of exhaustion genes.
    Journal • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    mezigdomide (CC-92480)
    5d
    Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer. (PubMed, J Proteome Res)
    Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.
    Journal
    |
    IKZF2 (IKAROS family zinc finger 2)
    |
    pomalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    19d
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    27d
    Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, University of Pittsburgh | N=30 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Opdivo (nivolumab) • golcadomide (CC-99282)
    27d
    MAGENTA: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=25, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Talvey (talquetamab-tgvs) • mezigdomide (CC-92480)
    28d
    24CH294: A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies - The IFM 2024-01 clinical trial (BELAMI) (2025-520976-25-00)
    P1/2, N=44, Not yet recruiting, Centre Hospitalier Universitaire De Saint Etienne
    New P1/2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    1m
    A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) (2025-521090-14-00)
    P1/2, N=70, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1/2 trial
    |
    carfilzomib • dexamethasone • mezigdomide (CC-92480)
    1m
    Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Abecma (idecabtagene vicleucel) • mezigdomide (CC-92480)
    1m
    Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gazyva (obinutuzumab) • golcadomide (CC-99282)
    1m
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    2ms
    A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov)
    P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Feb 2026 --> Jul 2026
    Trial primary completion date
    |
    carfilzomib • mezigdomide (CC-92480)
    2ms
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)